Business of Biotech shifts into human resources in a conversation with Vivek Ramaswamy, CEO of Roivant Sciences. Vivek Ramaswamy will share his learnings about the connections between building an all-star team, a promising therapy, and why people are the most important element of building legitimate company valuation.
By Anna Rose Welch, chief editor, Biosimilar Development
The first of this two-part article portrays the complex makeup of the Canadian healthcare system and current stakeholder needs as it relates to biosimilar switching, with a specific focus on the results of one private payer's transition program.
This article will examine the relationship between improved continuous manufacturing (CM) and biosimilar development, paying particular attention to the reasons why biosimilars are especially promising candidates for CM development and innovation.
Size exclusion chromatography is the go-to analytical method for therapeutic protein drugs. This article describes the factors affecting the reproducibility of columns and how you can minimize column variation.